Avastin

ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Biopharma Dive
insurers
Amgen
biosimilars
Avastin
Herceptin
Roche
UnitedHealthcare
Flag link:
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Fierce Pharma
Herceptin
Avastin
Roche
biosimilars
Allergan
Amgen
Flag link:
Another Biosimilar Approval From FDA, Another Unknown Launch Date
Another Biosimilar Approval From FDA, Another Unknown Launch Date
RAPS.org
Pfizer
Zirabev
biosimilars
FDA
Roche
cancer
Avastin
Flag link:
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
Fierce Biotech
AstraZeneca
Avastin
anti-VEGF
cediranib
Flag link:
Roche gets European approval for Tecentriq combo vs. lung cancer
Roche gets European approval for Tecentriq combo vs. lung cancer
Reuters
Roche
Europe
Tecentriq
Avastin
lung cancer
metastatic non-squamous non-small cell lung cancer
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
BioSpace
Genentech
FDA
Tecentriq
Avastin
non-squamous cell non-small cell lung cancer
Flag link:
One more shot at slowing Keytruda’s first-line lung cancer domination
One more shot at slowing Keytruda’s first-line lung cancer domination
EP Vantage
Keytruda
Merck
Roche
Tecentriq
Avastin
lung cancer
Flag link:
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Pharmaforum
UK
Roche
Avastin
wet age-related macular degeneration
Novartis
Bayer
Flag link:
In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
Endpoints
Genentech
Roch
Tecentriq
Avastin
lung cancer
FDA
Flag link:
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Fierce Pharma
Roche
Avastin
Tecentriq
lung cancer
Flag link:
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Flag link:
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
Flag link:
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Fierce Pharma
Roche
Pharma CEOs
Severin Schwan
biosimilars
Herceptin
Rituxan
Avastin
Flag link:
The 2018 biosimilar litigation landscape: A primer
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Flag link:
Roche's Fight With Pfizer May Be Just The Beginning
Roche's Fight With Pfizer May Be Just The Beginning
Forbes
Roche
Pfizer
Herceptin
biosimilars
cancer
Avastin
Rituxan
Flag link:
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation
Flag link:
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
Bloomberg
FDA
Avastin
biosimilars
Roche
Flag link:
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
Endpoints
FDA
Scott Gottlieb
Amgen
Allergan
biosimilars
Mvasi
Roche
Avastin
Flag link:

Pages